Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Concert Pharmaceutic (CNCE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Consolidated Research: 2018 Summary Expectations for Independent Bank Group, Concert Pharmaceuticals, Bank of Marin, Eclipse Resources, MKS Instruments, and Container Store -- Fundamental Analysis, Key Performance Indications

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Independent Bank Group, Inc...

MKSI : 91.40 (+0.16%)
CNCE : 16.39 (-0.12%)
BMRC : 87.00 (-0.80%)
ECR : 1.59 (-4.79%)
TCS : 12.02 (+5.62%)
IBTX : 68.55 (-0.87%)
Concert Pharmaceuticals (CNCE) Reports Q2 Loss, Misses Revenue Estimates

Concert (CNCE) delivered earnings and revenue surprises of 8.06% and -90.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

CNCE : 16.39 (-0.12%)
Concert Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Company Update

-- Conference Call Scheduled Today at 8:30 A.M. EDT --

CNCE : 16.39 (-0.12%)
Concert Pharmaceuticals to Report Second Quarter 2018 Financial Results on August 2, 2018

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its second quarter 2018 financial results on Thursday, August 2, 2018, before the U.S. financial markets...

CNCE : 16.39 (-0.12%)
Concert Pharmaceuticals Completes Enrollment in Phase 2a Trial of CTP-543 in Alopecia Areata

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has completed patient enrollment of its Phase 2a trial evaluating CTP-543 for the treatment of moderate-to-severe...

CNCE : 16.39 (-0.12%)
Concert Pharmace Set to Possibly Rebound After Yesterday's Selloff of 2.12%

Concert Pharmace (NASDAQ:CNCE) traded in a range yesterday that spanned from a low of $19.11 to a high of $20.13. Yesterday, the shares fell 2.1%, which took the trading range below the 3-day low of...

CNCE : 16.39 (-0.12%)
Stock Review for Biotech's Investors -- Concert Pharma, ContraVir Pharma, Corbus Pharma, and Corcept Therapeutics

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on CNCE, CTRV, CRBP, and CORT which can be accessed for free by signing up to www.wallstequities.com/registration....

CORT : 12.27 (-7.47%)
CNCE : 16.39 (-0.12%)
CRBP : 4.93 (-1.40%)
CTRV : 0.70 (-2.78%)
PROCESSA PHARMACEUTICALS ANNOUNCES THAT IT HAS BEEN ASSIGNED THE LICENSE FOR THE CLINICAL STAGE COMPOUND CTP-499 AND PLANS TO DEVELOP THE DRUG IN MULTIPLE UNMET MEDICAL NEED CONDITIONS

Processa Pharmaceuticals, Inc. (OTC: PCSA) announced today that, as agreed in the asset purchase of Promet Therapeutics, LLC, Processa has been assigned the license for CTP-499 upon Promet's exercising...

CNCE : 16.39 (-0.12%)
PCSA : 3.0000 (+0.67%)
Processa Pharmaceuticals Announces That It Has Been Assigned The License For The Clinical Stage Compound CTP-499 And Plans To Develop The Drug In Multiple Unmet Medical Need Conditions

Processa Pharmaceuticals, Inc. (OTC: PCSA) announced today that, as agreed in the asset purchase of Promet Therapeutics, LLC, Processa has been assigned the license for CTP-499 upon Promet's exercising...

CNCE : 16.39 (-0.12%)
PCSA : 3.0000 (+0.67%)
Concert Pharmaceuticals Present at Upcoming Investor Conferences

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the following upcoming investor conferences:

CNCE : 16.39 (-0.12%)
Concert Pharmaceuticals, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 1, 2018 / Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) will be discussing their earnings results in their Q4 Earnings Call to be held on March 1, 2018, at 8:30 AM Eastern...

CNCE : 16.39 (-0.12%)
Concert Pharmaceuticals Announces Advancement of Novel Drug Candidate in Schizophrenia

--Conference Call Scheduled Tomorrow at 8:30 a.m. ET for Company Update and 2017 Financial Results

CNCE : 16.39 (-0.12%)
Report: Developing Opportunities within M.D.C., Concert Pharmaceuticals, WellCare Health Plans, Dextera Surgical, Continental Resources, and Western Union -- Future Expectations, Projections Moving into 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of M.D.C. Holdings, Inc. (NYSE:MDC),...

CNCE : 16.39 (-0.12%)
DXTR : 0.0499 (+42.57%)
CLR : 63.30 (-2.28%)
WCG : 289.99 (+1.08%)
MDC : 30.69 (-1.45%)
WU : 18.75 (-0.48%)
Concert Pharmaceuticals to Report Full Year 2017 Results on March 1, 2018

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the year ended December 31, 2017, on Thursday, March 1, 2018, before the...

CNCE : 16.39 (-0.12%)
Vertex's Third Cystic Fibrosis Treatment Gets FDA Approval

Vertex???s (VRTX) FDA approved tezacaftor/ivacaftor combination for cystic fibrosis in patients with certain mutations in the CFTR gene marks the indication???s third treatment.

XOMA : 16.19 (-12.15%)
CNCE : 16.39 (-0.12%)
VRTX : 175.05 (+0.13%)
EXEL : 19.64 (-3.73%)
Concert Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Company Update

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the third quarter of 2017.

CNCE : 16.39 (-0.12%)
Concert Pharmaceuticals Announces Completion of Enrollment in First Cohort of CTP-543 Phase 2a Trial

--Phase 2a Trial On Track to Complete in Second Half of 2018

CNCE : 16.39 (-0.12%)
Concert Pharmaceuticals to Report Third Quarter 2017 Financial Results on November 9, 2017, and Participate at Upcoming Investor Conferences

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its third quarter 2017 financial results on Thursday, November 9, 2017, before the U.S. financial markets...

CNCE : 16.39 (-0.12%)
Flex Pharma Names Dr. Roger Tung to Its Board of Directors

Click to Tweet this News

CNCE : 16.39 (-0.12%)
FLKS : 0.65 (+3.17%)
Concert Pharmaceuticals Announces PTAB Denies Incyte Petition Challenging CTP-543 Patent

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the Patent Trials and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has denied Incyte's petition to...

CNCE : 16.39 (-0.12%)

Van Meerten Stock Picks

5 Terrific Mid Caps
In this roller coaster market I wanted to find Mid Cap stocks that had consistent price appreciation over the last 6 month period.
EHC +0.54 , FTNT -0.51 , CAKE +0.54 , PLT +0.33 , AEO -0.09
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures weekly newsletter features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Friday morning to your inbox.

Agricharts Market Commentary

Today's Commentary

Corn futures ended the Monday session with most contracts 1 to 2 cents in the red. The USDA reported a private export sale of 213,372 MT to Mexico this morning, with the sale split between 2018/19 (142,248 MT) and 19/20 (71,124 MT). This morning&r...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar